Precigen, Inc. (PGEN) stock
PGENNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30239% above fair value
$4.54−0.12 (-2.58%)
Close on Nov 13, 2026Market cap $1.63BP/E 113.5Yield –
Precigen enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Precigen's enterprise value was $1.74B on Nov 11, 2026, against $1.23B a year earlier. Over the last 5 years it ranged from $179.61M to $3.12B, with a median of $358.97M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $1.74B | +28.8% |
| 2025 | Dec 31, 2025 | $1.36B | +352.7% |
| 2024 | Dec 31, 2024 | $299.38M | +11.1% |
| 2023 | Dec 29, 2023 | $269.56M | +10.3% |
| 2022 | Dec 30, 2022 | $244.32M | -70.6% |
| 2021 | Dec 31, 2021 | $832.33M | -56.3% |
| 2020 | Dec 31, 2020 | $1.90B | +87.3% |
| 2019 | Dec 31, 2019 | $1.02B | +20.6% |
| 2018 | Dec 31, 2018 | $842.65M | -35.2% |
| 2017 | Dec 29, 2017 | $1.30B | -51.0% |
| 2016 | Dec 30, 2016 | $2.65B | -19.9% |
| 2015 | Dec 31, 2015 | $3.31B | +23.8% |
| 2014 | Dec 31, 2014 | $2.68B | +25.8% |
| 2013 | Dec 31, 2013 | $2.13B | – |
See a number that looks wrong?